Positive News SentimentPositive News Monte Rosa Therapeutics Stock Price, News & Analysis (NASDAQ:GLUE) $3.12 +0.02 (+0.65%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$2.92▼$3.1650-Day Range$2.50▼$6.3952-Week Range$2.44▼$9.83Volume346,068 shsAverage Volume182,680 shsMarket Capitalization$156.25 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Monte Rosa Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside327.4% Upside$13.33 Price TargetShort InterestBearish9.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.56) to ($2.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector446th out of 952 stocksBiological Products, Except Diagnostic Industry74th out of 161 stocks 3.3 Analyst's Opinion Consensus RatingMonte Rosa Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, Monte Rosa Therapeutics has a forecasted upside of 327.4% from its current price of $3.12.Amount of Analyst CoverageMonte Rosa Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.69% of the float of Monte Rosa Therapeutics has been sold short.Short Interest Ratio / Days to CoverMonte Rosa Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Monte Rosa Therapeutics has recently decreased by 8.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMonte Rosa Therapeutics does not currently pay a dividend.Dividend GrowthMonte Rosa Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLUE. Previous Next 3.3 News and Social Media Coverage News SentimentMonte Rosa Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Monte Rosa Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GLUE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Monte Rosa Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Monte Rosa Therapeutics is held by insiders.Percentage Held by Institutions80.05% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.56) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Monte Rosa Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Monte Rosa Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMonte Rosa Therapeutics has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Monte Rosa Therapeutics Stock (NASDAQ:GLUE)Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.Read More GLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLUE Stock News HeadlinesNovember 21, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNovember 14, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)December 2, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)November 9, 2023 | benzinga.comMonte Rosa Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 9, 2023 | finance.yahoo.comMonte Rosa Therapeutics Inc (GLUE) Reports Q3 2023 Financial Results and Strategic DevelopmentsNovember 7, 2023 | finance.yahoo.comMonte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 31, 2023 | nasdaq.comMonte Rosa Therapeutics, Inc. Common Stock (GLUE)October 31, 2023 | msn.comMonte Rosa Therapeutics: Roche Partnership Deal Could Bring Added ValueOctober 30, 2023 | marketwatch.comMonte Rosa Therapeutics Shares Rise for Second Session in a RowOctober 26, 2023 | msn.comMonte Rosa Therapeutics prices offering to raise $25MOctober 26, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesOctober 24, 2023 | finance.yahoo.comDown -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)October 20, 2023 | msn.comJP Morgan Maintains Monte Rosa Therapeutics (GLUE) Overweight RecommendationOctober 17, 2023 | bizjournals.comRoche signs $2.5B deal with Boston's Monte Rosa TherapeuticsOctober 17, 2023 | msn.comRoche in pact with Monte Rosa to develop cancer and neuro drugsOctober 17, 2023 | markets.businessinsider.comMonte Rosa Therapeutics Inks Strategic Collaboration With Roche To Develop Molecular Glue DegradersOctober 17, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsOctober 17, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesSeptember 16, 2023 | finance.yahoo.comGLUE - Monte Rosa Therapeutics, Inc.August 10, 2023 | finanznachrichten.deMonte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 10, 2023 | finance.yahoo.comMonte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 27, 2023 | finance.yahoo.comMonte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of DirectorsJuly 16, 2023 | finance.yahoo.comWe're Keeping An Eye On Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn RateMay 30, 2023 | finance.yahoo.comMonte Rosa Therapeutics to Present at Upcoming Investor and Industry ConferencesSee More Headlines Receive GLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLUE CUSIPN/A CIK1826457 Webwww.monterosatx.com Phone617-949-2643FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$13.33 High Stock Price Target$18.00 Low Stock Price Target$11.00 Potential Upside/Downside+327.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-58.20% Return on Assets-44.96% Debt Debt-to-Equity RatioN/A Current Ratio8.09 Quick Ratio8.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.68 per share Price / Book0.85Miscellaneous Outstanding Shares50,080,000Free Float47,427,000Market Cap$156.25 million OptionableNot Optionable Beta0.99 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Markus Warmuth M.D. (Age 52)President, CEO & Director Comp: $901.35kDr. Owen B. Wallace Ph.D. (Age 54)Chief Scientific Officer Comp: $630.68kDr. Filip Janku M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $658.66kMs. Jennifer ChampouxChief People & Operations OfficerDr. Sharon Townson Ph.D. (Age 48)Chief Technology Officer Mr. Philip Nickson J.D. (Age 44)Ph.D., General Counsel Dr. John C. Castle Ph.D. (Age 52)Chief Data Scientist Dr. Jullian G. Jones J.D. (Age 47)M.B.A., Ph.D., Chief Business Officer Mr. Magnus Walter DPHILSenior Vice President of Chemical Sciences & Process DevelopmentMr. Edmund Dunn (Age 57)Vice President & Corporate Controller More ExecutivesKey CompetitorsDBV TechnologiesNASDAQ:DBVTKodiak SciencesNASDAQ:KODSutro BiopharmaNASDAQ:STROMolecular PartnersNASDAQ:MOLNGenfitNASDAQ:GNFTView All CompetitorsInstitutional OwnershipAmerican Century Companies Inc.Bought 6,879 shares on 11/30/2023Ownership: 0.040%Legal & General Group PlcBought 6,469 shares on 11/15/2023Ownership: 0.069%California State Teachers Retirement SystemSold 3,218 shares on 11/14/2023Ownership: 0.088%Trexquant Investment LPBought 10,935 shares on 11/14/2023Ownership: 0.051%Corton Capital Inc.Bought 14,460 shares on 11/14/2023Ownership: 0.029%View All Institutional Transactions GLUE Stock Analysis - Frequently Asked Questions Should I buy or sell Monte Rosa Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GLUE shares. View GLUE analyst ratings or view top-rated stocks. What is Monte Rosa Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued 12 month target prices for Monte Rosa Therapeutics' shares. Their GLUE share price targets range from $11.00 to $18.00. On average, they predict the company's share price to reach $13.33 in the next year. This suggests a possible upside of 327.4% from the stock's current price. View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts. How have GLUE shares performed in 2023? Monte Rosa Therapeutics' stock was trading at $7.61 on January 1st, 2023. Since then, GLUE shares have decreased by 59.0% and is now trading at $3.12. View the best growth stocks for 2023 here. When is Monte Rosa Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our GLUE earnings forecast. How were Monte Rosa Therapeutics' earnings last quarter? Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) posted its earnings results on Thursday, November, 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.05. What ETF holds Monte Rosa Therapeutics' stock ? Range Cancer Therapeutics ETF holds 18,664 shares of GLUE stock, representing 1.26% of its portfolio. When did Monte Rosa Therapeutics IPO? (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at $17.00-$19.00 per share. Who are Monte Rosa Therapeutics' major shareholders? Monte Rosa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (11.99%), Northern Trust Corp (0.89%), Charles Schwab Investment Management Inc. (0.49%), TD Asset Management Inc (0.39%), California State Teachers Retirement System (0.09%) and Legal & General Group Plc (0.07%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L. How do I buy shares of Monte Rosa Therapeutics? Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GLUE) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.